Patents by Inventor Edward Namserk Cha

Edward Namserk Cha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATMENT OF CANCER WITH AN ANTI-TIGIT ANTAGONIST ANTIBODY
    Publication number: 20220016243
    Abstract: The present invention relates to methods, uses, and compositions for the treatment of cancer (e.g., a lung cancer; a cervical cancer; a breast cancer; a head and neck cancer; a liver cancer; a bladder cancer; a gastric cancer; an esophageal cancer; a pancreatic cancer; a kidney or renal cancer; a melanoma; an ovarian cancer; or a colorectal cancer). More specifically, the invention concerns the treatment of patients having cancer with an anti-TIGIT antagonist antibody, including treatment with an anti-TIGIT antagonist antibody in a combination therapy.
    Type: Application
    Filed: January 26, 2021
    Publication date: January 20, 2022
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Catherine LAI, Janet LAU, Anthony Jongha LEE, Shi LI, Yvonne Gail LIN-LIU, Christina Jeanne MATHENY, Diana MENDUS, Raymond D. MENG, Anh NGUYEN DUC, Jilpa Bhupendra PATEL, Thinh Quang PHAM, Isabelle Anne ROONEY, Heather Blythe STEVENS, Sarah Marie TROUTMAN, Lijia WANG, Yulei WANG, Patrick Georges Robert WILLIAMS, Benjamin WU, Yibing YAN, Aijing ZHANG, Xiaosong ZHANG, Marcus Dale BALLINGER, Hila BARAK, Elizabeth Alexandra BENNETT, Marcela Lucia CASTRO, Edward Namserk CHA, Hui Min Phyllis CHAN, Stephen CHUI, Christopher Roland COTTER, Viraj Vinay DEGAONKAR, Barbara Jennifer GITLITZ, Tien HOANG, Kimberly Mayumi KOMATSUBARA
  • TREATMENT WITH ANTI-TIGIT ANTIBODIES AND PD-1 AXIS BINDING ANTAGONISTS
    Publication number: 20210395366
    Abstract: The present invention relates to the treatment of esophageal cancer, e.g., esophageal squamous cell carcinoma (ESCC) (e.g., advanced ESCC (e.g., unresectable, locally advanced, recurrent, and/or metastatic ESCC)). More specifically, the invention pertains to the treatment of patients having esophageal cancer by administering a combination of an anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) antagonist antibody and a programmed death-1 (PD-1) axis binding antagonist.
    Type: Application
    Filed: January 26, 2021
    Publication date: December 23, 2021
    Inventors: Shi LI, Meghna Das Thakur HARRIS, Yifan WANG, Edward Namserk CHA, Feijiao GE
  • COMBINATION THERAPY FOR CANCER COMPRISING PD-1 AXIS BINDING ANTAGONIST AND IL6 ANTAGONIST
    Publication number: 20210332143
    Abstract: This application discloses methods and compositions for use in treating cancer, including breast cancer (such as metastatic triple negative breast cancer, mTNBC), urothelial carcinoma, renal cell carcinoma, and liver cancer (hepatocellular carcinoma, HCC) with the combination of a PD-1 axis binding antagonist (e.g., a PD-L1 binding antibody such as atezolizumab) and an IL6 antagonist (e.g. an anti-IL6 receptor antibody such as tocilizumab), optionally further comprising a VEGF antagonist (e.g. an anti-VEGF antibody such as bevacizumab). Optionally, the patient has C-reactive protein (CRP) and/or IL-6 level(s) above the upper limit of normal. Optionally, the cancer is PD-L1 positive.
    Type: Application
    Filed: March 4, 2021
    Publication date: October 28, 2021
    Applicant: Genentech, Inc.
    Inventors: Mahrukh Huseni, Joanna E. Klementowicz, Yijin Li, Li-Fen Liu, Sanjeev Mariathasan, Mark Merchant, Luciana Molinero, Lifen Wang, Nathaniel West, Patrick Williams, Chi Yung Yuen, Edward Namserk Cha, Yulei Wang
  • TREATMENT OF TRIPLE NEGATIVE BREAST CANCER OR COLORECTAL CANCER WITH LIVER METASTASES WITH AN ANTI PD-L1 ANTIBODY AND AN ONCOLYTIC VIRUS
    Publication number: 20200254037
    Abstract: Provided herein are methods of treating a subject with triple negative breast cancer or colorectal cancer. In exemplary embodiments, the method comprises administering to the subject a combination of an oncolytic virus, such as talimogene laherparepvec, and an anti-PD-L1 antibody, such as atezolizumab. In exemplary aspects, the oncolytic virus is administered to the subject at an initial dose followed by a second dose, wherein the initial dose is lower than the second dose. In exemplary aspects, the oncolytic virus is intrahepatically administered to the subject.
    Type: Application
    Filed: August 6, 2018
    Publication date: August 13, 2020
    Inventors: Jennifer Lorraine Gansert, Sumita Shankar Bhatta, Joseph Paul Woodard, JR., Edward Namserk Cha